{"id":"grippol-quadrivalent","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) influenza virus particles or antigens from four different influenza strains (two A subtypes and two B lineages). Upon administration, it triggers both humoral and cellular immune responses, leading to the production of strain-specific antibodies and T-cell immunity that protect against infection with matching circulating influenza viruses.","oneSentence":"Grippol Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:25.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT03849560","phase":"PHASE2, PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":"Influenza","enrollment":612},{"nctId":"NCT06385821","phase":"PHASE3","title":"A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2022-09-21","conditions":"Influenza, Influenza A, Influenza, Human","enrollment":824}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Grippol Quadrivalent","genericName":"Grippol Quadrivalent","companyName":"NPO Petrovax","companyId":"npo-petrovax","modality":"Biologic","firstApprovalDate":"","aiSummary":"Grippol Quadrivalent is an influenza vaccine used to prevent Influenza, Influenza A, Influenza Type B, and Flu. It is developed by NPO Petrovax and is studied in clinical trials for its safety, reactogenicity, immunogenicity, and efficacy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}